Benzinga
Benzinga
Benzinga
sábado, septiembre 26

Oruka Therapeutics Inc

ORKANASDAQ
Trade with Public
Trade with Public
$84.46
-1.03-1.2%
al cierre: Sep 25, 5:00 PM EST
$86.00
1.541.82%
After hour: 9:27 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadDividendosCompararOpcionesInforme de acciones

Oruka Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Oruka Therapeutics (ORKA).

Price Target Range — 9 Quarters

Analyst Consensus — 15 Analysts

15Buy
Consensus RatingBuy# Analysts15Avg. Consensus PT$87Upside to Avg. PT+1.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →
DateFirmAnalystActionRating ChangePrice Target
Sep 24, 2026WedbushMartin Fan MaintainedOutperform$165
Sep 24, 2026HC Wainwright & Co.Mitchell S. KapoorMaintainedBuy$120
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target

Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target

Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target

BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved